JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dhein, S.
Right arrow Articles by Raschack, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dhein, S.
Right arrow Articles by Raschack, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetic Kidney Problems

Vol. 293, Issue 2, 351-359, May 2000

Long-Term Effects of the EndothelinA Receptor Antagonist LU 135252 and the Angiotensin-Converting Enzyme Inhibitor Trandolapril on Diabetic Angiopathy and Nephropathy in a Chronic Type I Diabetes Mellitus Rat Model

Stefan Dhein, Stefan Hochreuther, Christian aus dem Spring, Klaus Bollig, Christine Hufnagel and Manfred Raschack

Institute of Pharmacology, University of Halle, Halle, Germany (S.D.); Institute of Pharmacology, University of Cologne, Cologne, Germany (S.H., C.a.d.S., K.B.); and Knoll AG, Ludwigshafen, Germany (C.H., M.R.)

Diabetic angiopathy is a serious problem in antidiabetic therapy. We wanted to investigate whether treatment with the endothelinA receptor antagonist LU 135252 or with the angiotensin-converting enzyme inhibitor trandolapril might prevent angiopathy in long-term type I diabetes mellitus. Six groups of male Wistar rats were investigated: untreated age-matched control rats, healthy controls treated with trandolapril (0.3 mg/kg), healthy controls treated with LU 135252 (100 mg/kg), untreated diabetic rats, and diabetic rats treated with either trandolapril or LU 135252. Rats were rendered diabetic by injection of streptozotozin. Duration of the disease was 6 months. Thereafter, rats were sacrificed, and hearts, kidneys, and a mesenterial loop were removed. Hearts and kidneys were processed histologically; the mesenterial loop was perfused with saline at constant pressure for investigation of microvessels using microvideoangiometry while treated with either 30 mM KCl, 1 µM acetylcholine, or 1 µM sodium nitroprusside. All diabetic rats developed hyperglycemia without differences among these three groups. Diabetic rats exhibited marked anemia, which was significantly antagonized by both treatments. The heart capillaries/muscle fibers ratio was decreased significantly in diabetic animals, which was prevented fully by both treatments. Renal glomerular diameter was increased in diabetic rats. This was significantly antagonized by LU 135252 but not by trandolapril. Deposition of homogeneous eosinophilic material within the glomeruli was nearly completely prevented by LU 135252. The acetylcholine-induced vasodilation in mesenteric microvessels was significantly attenuated in diabetic rats, which was significantly antagonized by both treatments. We conclude that both angiotensin and endothelin seem to contribute to the development of diabetic angiopathy and that, in addition to angiotensin-converting enzyme inhibition, blockade of endothelinA receptors may be an interesting new approach to antiangiopathic therapy.


0022-3565/00/2932-0351$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Histochem. Cytochem.Home page
M. Wendel, L. Knels, W. Kummer, and T. Koch
Distribution of Endothelin Receptor Subtypes ETA and ETB in the Rat Kidney
J. Histochem. Cytochem., November 1, 2006; 54(11): 1193 - 1203.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
S. Jesmin, S. Zaedi, N. Yamaguchi, S. Maeda, I. Yamaguchi, K. Goto, and T. Miyauchi
Effects of dual endothelin receptor antagonist on antiapoptotic marker bcl-2 expression in streptozotocin-induced diabetic rats.
Experimental Biology and Medicine, June 1, 2006; 231(6): 1034 - 1039.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
T. Pfab, C. Thone-Reineke, F. Theilig, I. Lange, H. Witt, C. Maser-Gluth, M. Bader, J.-P. Stasch, P. Ruiz, S. Bachmann, et al.
Diabetic Endothelin B Receptor-Deficient Rats Develop Severe Hypertension and Progressive Renal Failure
J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1082 - 1089.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
V. Portik-Dobos, A. K. Harris, W. Song, J. Hutchinson, M. H. Johnson, J. D. Imig, D. M. Pollock, and A. Ergul
Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2006; 290(2): R435 - R441.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg
From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines
Endocr. Rev., December 1, 2004; 25(6): 971 - 1010.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
A. Sorokin and D. E. Kohan
Physiology and pathology of endothelin-1 in renal mesangium
Am J Physiol Renal Physiol, October 1, 2003; 285(4): F579 - F589.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Dhein, A. Kabat, A. Olbrich, P. Rosen, H. Schroder, and F.-W. Mohr
Effect of Chronic Treatment with Vitamin E on Endothelial Dysfunction in a Type I in Vivo Diabetes Mellitus Model and in Vitro
J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 114 - 122.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.